Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib-Reference-Cited by-同舟云学术

Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib

Published:2023-09-15 Issue:18 Volume:62 Page:2693-2698
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Arai Hiroyuki¹,Yamamoto Shinya¹,Matsubara Takeshi¹,Miyake Takafumi¹,Tochio Akira¹,Mii Akiko²,Shimizu Akira³,Minamiguchi Sachiko⁴,Muso Eri⁵,Yanagita Motoko¹

Affiliation:

1. Department of Nephrology, Kyoto University Graduate School of Medicine, Japan

2. Department of Nephrology, Nippon Medical School, Japan

3. Department of Analytic Human Pathology, Nippon Medical School, Japan

4. Department of Diagnostic Pathology, Kyoto University Hospital, Japan

5. Division of Nephrology and Dialysis, Kitano Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/18/62_1283-22/_pdf

Reference28 articles.

1. 1. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30: 187-200, 2019.

2. 2. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367: 2075-2088, 2012.

3. 3. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132: 393-404, 2018.

4. 4. Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther 12: 635-645, 2019.

5. 5. Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep 2: 108-123, 2017.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib/nilotinib/ponatinib;Reactions Weekly;2023-10-14

2. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists;International Journal of Clinical Oncology;2023-03-05